Study of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men With Metastatic Castration-Resistant Prostate Cancer (PROfound Study)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2017
The purpose of this study is to evaluate the efficacy and safety of olaparib versus enzalutamide or abiraterone acetate in subjects with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have homologous recombination repair gene mutations.
Epistemonikos ID: 7dd35ca0a8a3d28526ac416dffa80ba3fe0d763e
First added on: Jun 24, 2022